These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19945743)

  • 1. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
    Taylor DD; Atay S; Metzinger DS; Gercel-Taylor C
    Gynecol Oncol; 2010 Feb; 116(2):213-21. PubMed ID: 19945743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
    Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
    Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients.
    Chinni SR; Falchetto R; Gercel-Taylor C; Shabanowitz J; Hunt DF; Taylor DD
    Clin Cancer Res; 1997 Sep; 3(9):1557-64. PubMed ID: 9815843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer.
    Gerçel-Taylor C; Bazzett LB; Taylor DD
    Gynecol Oncol; 2001 Apr; 81(1):71-6. PubMed ID: 11277653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
    Taylor DD; Lyons KS; Gerçel-Taylor C
    Gynecol Oncol; 2002 Mar; 84(3):443-8. PubMed ID: 11855885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
    Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
    J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
    Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
    Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA).
    Hamrita B; Chahed K; Kabbage M; Guillier CL; Trimeche M; Chaïeb A; Chouchane L
    Clin Chim Acta; 2008 Jul; 393(2):95-102. PubMed ID: 18424265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
    Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
    Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
    Barua A; Bradaric MJ; Kebede T; Espionosa S; Edassery SL; Bitterman P; Rotmensch J; Luborsky JL
    Am J Reprod Immunol; 2007 Apr; 57(4):243-9. PubMed ID: 17362385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
    Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
    Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of serum biomarkers for detection of early stage ovarian cancer.
    Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
    Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
    Taylor DD; Gercel-Taylor C; Parker LP
    Gynecol Oncol; 2009 Oct; 115(1):112-120. PubMed ID: 19647308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells.
    Savage HE; Rossen RD; Hersh EM; Freedman RS; Bowen JM; Plager C
    Cancer Res; 1986 Apr; 46(4 Pt 2):2127-33. PubMed ID: 3948184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope recognition by anti-cathepsin D autoantibodies in endometrial cancer patients.
    Bosscher JR; Gerçel-Taylor C; Watkins CS; Taylor DD
    Gynecol Oncol; 2001 May; 81(2):138-43. PubMed ID: 11330940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Purification and characterization of corresponding antigen recognized by monoclonal antibody 183B2 against ovarian carcinoma].
    Guo HF; Feng J; Zhang H; Yao Y; Cheng HY
    Zhonghua Fu Chan Ke Za Zhi; 2005 Sep; 40(9):614-8. PubMed ID: 16202318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic studies of early-stage and advanced ovarian cancer patients.
    Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
    Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
    Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
    Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
    Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
    Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of malignant ovarian neoplasms: a review of the literature. III. Immunological detection and ovarian cancer-associated antigens.
    Smith LH; Oi RH
    Obstet Gynecol Surv; 1984 Jun; 39(6):346-60. PubMed ID: 6203071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.